SPOTLIGHT: JAMA editor scolds Pfizer for subpoenas

The Journal of the American Medical Association lambasted Pfizer for threatening the "integrity" of its peer-review-based decision-making system by subpoenaing peer reviews for its Celebrex and Bextra defense. After posting that editorial on JAMA's website, editor Catherine DeAngelis told the WSJ Health Blog that a medical journal "may as well pack it up and go home" if it gave drugmakers the kind of information Pfizer wanted. Report

Suggested Articles

Eli Lilly and Incyte are investing heavily in JAK inhibitor Olumiant's chances in atopic dermatitis, but does it stand a chance against Dupixent?

Krystal Biotech has started on a new manufacturing facility for eventual commercial supply of gene therapies in its pipeline.

Chinese authorities have recommended trying AbbVie's HIV combo therapy Kaletra to treat the new coronavirus ravaging the country—and spreading fast.